Barclays PLC Increases Stake in Inovio Pharmaceuticals, Inc. (NASDAQ:INO)

Barclays PLC boosted its position in Inovio Pharmaceuticals, Inc. (NASDAQ:INO) by 282.6% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 34,003 shares of the biopharmaceutical company’s stock after acquiring an additional 25,116 shares during the period. Barclays PLC owned 0.13% of Inovio Pharmaceuticals worth $197,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in INO. State Street Corp raised its position in shares of Inovio Pharmaceuticals by 11.7% in the third quarter. State Street Corp now owns 490,662 shares of the biopharmaceutical company’s stock valued at $2,836,000 after purchasing an additional 51,414 shares during the period. Bank of New York Mellon Corp bought a new stake in Inovio Pharmaceuticals during the 2nd quarter valued at $661,000. Dimensional Fund Advisors LP purchased a new stake in shares of Inovio Pharmaceuticals during the second quarter worth $605,000. Wellington Management Group LLP purchased a new stake in shares of Inovio Pharmaceuticals during the third quarter worth $379,000. Finally, Rhumbline Advisers boosted its holdings in shares of Inovio Pharmaceuticals by 5,943.0% in the second quarter. Rhumbline Advisers now owns 38,494 shares of the biopharmaceutical company’s stock worth $311,000 after acquiring an additional 37,857 shares during the period. 26.79% of the stock is owned by hedge funds and other institutional investors.

Inovio Pharmaceuticals Stock Performance

Inovio Pharmaceuticals stock opened at $1.93 on Tuesday. The business has a 50-day simple moving average of $3.69 and a 200 day simple moving average of $6.25. Inovio Pharmaceuticals, Inc. has a 52 week low of $1.74 and a 52 week high of $14.75.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on INO. Oppenheimer decreased their price objective on Inovio Pharmaceuticals from $33.00 to $15.00 and set an “outperform” rating on the stock in a research note on Monday, November 18th. HC Wainwright decreased their price target on Inovio Pharmaceuticals from $12.00 to $5.00 and set a “neutral” rating on the stock in a research report on Monday, November 18th. Finally, Royal Bank of Canada cut their price objective on shares of Inovio Pharmaceuticals from $7.00 to $6.00 and set a “sector perform” rating for the company in a research report on Friday, November 15th. One research analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $11.50.

Inovio Pharmaceuticals Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.